TheraDiag SA (ENXTPA:ALTER) entered into a PACEO standby equity facility with Société Générale on April 8, 2014. The funding will be received in tranches over a period of 24 months with issuance of up to 445,000 shares. The shares will be issued at a price equal to the volume-weighted average price of shares for the three trading days immediately preceding the issue date, minus a discount of not more than 5%. The transaction has been approved by shareholders of the company at the Annual General Meeting. The investor will acquire 9.9% of the number of shares currently outstanding. The stake of investors holding 1% stake in the company will reduce to 0.91% upon closing. Société Générale will act as placement agent to the company. Samuel Pallotto, Mathilde Cazé, Abel Colomb, and Jean-Philippe Mas of Brunswick Société d'Avocats will act as legal advisors to the company. On November 20, 2015, the company renewed the equity line facility. The company will issue a maximum of 550,000 shares in the transaction which represents 9.67% of the equity capital in the company. On January 16, 2015, the company renewed the equity line facility. The company will issue a maximum of 500,000 shares in the transaction which represents 9.64% of the equity capital in the company. On the assumption of a complete use of the line, a shareholder which owns 1% of the capital would see its stake by passing to 0.91% of the capital. The transaction is expected to close in the next 24 months. On January 16, 2017, Theradiag SA (ENXTPA:ALTER) closed the transaction.